September 21, 2016 / 1:28 AM / 10 months ago

BRIEF-biOasis enters into a license agreement with Vaccinex Inc.

1 Min Read

Sept 20 (Reuters) -

* biOasis enters into a license agreement with Vaccinex Inc.

* biOasis Technologies Inc - Says under terms of agreement, Vaccinex will have right to commercialize its anti-Semaphorin 4D antibody technology

* biOasis Technologies Inc - Under terms, Bioasis could receive up to $20 million in form of upfront and milestone payments

* biOasis Technologies Inc - Under terms of agreement, Vaccinex has been provided rights to transcend technology and its intellectual (patent) property Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below